Sugiyama M, Yamane H, Cho J S, Okada H, Sugita M, Nakai Y
Arch Otorhinolaryngol. 1986;243(5):281-7. doi: 10.1007/BF00460202.
Although the drug OK-432 can induce the release of gamma-interferon (IFN-gamma), the serum concentrations of IFN-gamma produced are very low. We studied the effects of combining OK-432 with alpha-interferon (IFN-alpha) on the endogenous production of IFN and the postoperative courses of patients with oral cavity cancers. Forty patients operated on for head and neck cancers were studied. Each patient was given an injection of OK-432 1 week after surgery. Between 10 and 14 days later, a combination of OK-432 and IFN-alpha was given to assess the effects of the concomitant use of IFN-alpha on IFN production. In 18 of the 30 patients given a large dose of IFN-alpha (3 or 5 X 10(6) IU/mg protein), IFN production induced by OK-432 was enhanced. A small dose of IFN-alpha (7 X 10(3) IU) did not enhance the action of OK-432. OK-432 also induced the release of both endogenous IFN-gamma and IFN-alpha, and the production of both types of IFN was enhanced by the concomitant administration of parenteral IFN-alpha. Next, 50 patients operated on for oral cavity cancers were given OK-432 or a combination of OK-432 and IFN-alpha for 4 months, and their postoperative courses were followed for 2-5 years. The clinical courses were better in the combined therapy group than in the group given OK-432 alone.
尽管溶链菌制剂（OK-432）能诱导γ-干扰素（IFN-γ）的释放，但所产生的IFN-γ血清浓度非常低。我们研究了将OK-432与α-干扰素（IFN-α）联合使用对IFN内源性产生及口腔癌患者术后病程的影响。对40例接受头颈部癌手术的患者进行了研究。每位患者在术后1周注射一次OK-432。在10至14天后，给予OK-432与IFN-α的联合制剂，以评估同时使用IFN-α对IFN产生的影响。在30例给予大剂量IFN-α（3或5×10⁶IU/mg蛋白质）的患者中，有18例OK-432诱导的IFN产生增强。小剂量的IFN-α（7×10³IU）并未增强OK-432的作用。OK-432还诱导内源性IFN-γ和IFN-α的释放，并且两种类型IFN的产生都通过胃肠外给予IFN-α而增强。接下来，对50例接受口腔癌手术的患者给予OK-432或OK-432与IFN-α的联合制剂治疗4个月，并对他们的术后病程进行了2至5年的随访。联合治疗组的临床病程比单独给予OK-432的组更好。
